TY - JOUR
T1 - Next Generation Immuno-Oncology Strategies
T2 - Unleashing NK Cells Activity
AU - Mendoza-Valderrey, Alberto
AU - Alvarez, Maite
AU - De Maria, Andrea
AU - Margolin, Kim
AU - Melero, Ignacio
AU - Ascierto, Maria Libera
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.
AB - In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.
KW - NK cell-based therapy
KW - antibody-based therapeutics
KW - cancer immunotherapy
KW - cytokine therapy
KW - innate immunity
KW - natural killer cells
UR - http://www.scopus.com/inward/record.url?scp=85139777263&partnerID=8YFLogxK
U2 - 10.3390/cells11193147
DO - 10.3390/cells11193147
M3 - Review article
C2 - 36231109
AN - SCOPUS:85139777263
SN - 2073-4409
VL - 11
JO - Cells
JF - Cells
IS - 19
M1 - 3147
ER -